相关临床试验
520
18 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1873
进行中（未招募）
13
2.5%
Approved For Marketing
1
0.2%
已完成
381
73.3%
Enrolling By Invitation
3
0.6%
尚未招募
2
0.4%
招募中
13
2.5%
终止
61
11.7%
Unknown
2
0.4%
撤回
44
8.5%
暂无批准数据
- Dolly Parton told her sister Stella that if there was "no hope" in her cancer battle, she would still allow her medical team to try experimental drugs to help others in the future. - Stella Parton revealed the request in an emotional Facebook tribute following the country music icon's death after a brief battle with cancer at age 80. - The late icon was admitted to a Nashville hospital late last week after dealing with kidney and autoimmune issues, according to her sister. - Parton's lifetime of philanthropy included a $1 million donation to Vanderbilt University's COVID-19 research that contributed to the development of the Moderna vaccine.
- Bright Minds Biosciences has initiated a Phase 2a NOVA study to evaluate BMB-101, a novel 5-HT2C receptor agonist, for treating hyperphagia and neuropsychiatric symptoms in Prader-Willi syndrome patients. - The company nominated BMB-105 as a dedicated clinical candidate for PWS, with plans to reduce time to market by approximately one year through this dual-compound development strategy. - BMB-101 has demonstrated strong safety profile in Phase 1 studies with 64 healthy volunteers, showing no serious adverse events and robust central target engagement through biomarker studies. - The 16-week randomized, double-blind study will assess efficacy using the Hyperphagia Questionnaire for Clinical Trials as the primary endpoint, targeting a rare genetic disorder affecting one in 15,000 births.
- Neumora Therapeutics has launched a Phase 1 single-ascending dose/multiple-ascending dose study of NMRA-898, the second M4 muscarinic receptor positive allosteric modulator in its schizophrenia-focused franchise. - NMRA-898 is structurally distinct from NMRA-861 and demonstrated no convulsions in preclinical studies across multiple species, offering potential best-in-class pharmacology for neuropsychiatric disorders. - The company now has two M4 PAMs in clinical development, providing strategic flexibility to advance one or both programs based on safety and pharmacokinetic data expected by mid-2026. - This approach targets the M4 muscarinic receptor rather than traditional D2 dopamine receptor blockade, potentially avoiding serious side effects that cause 75% of schizophrenia patients to discontinue current medications within 18 months.
- Virtuoso Surgical's robotic system received FDA Breakthrough Device Designation for bladder lesion removal via en bloc excision, positioning the company at the forefront of innovative bladder cancer care. - The system utilizes needle-sized robotic arms to enhance precision in minimally invasive endoscopic surgery, addressing significant clinical needs for improved specimen quality and cancer staging. - Recent randomized studies show manually performed en bloc techniques can lower one-year cancer recurrence rates versus standard TURBT, with Virtuoso aiming to enable widespread adoption through robotic assistance. - The FDA designation accelerates development and review processes, highlighting the system's potential to address critical gaps in bladder lesion removal compared to current endoscopic approaches.
- iMDx has enrolled its first patient in the GraftAssureDx clinical trial, an observational study designed to validate a kitted transplant rejection monitoring test for kidney transplant recipients. - The trial now includes 10 leading transplant centers, up from five previously, with plans to enroll up to 125 patients by year-end. - The company remains on track for FDA submission by end of 2025 and commercial launch in 2026, targeting the estimated $1 billion addressable market for kitted transplant rejection testing. - GraftAssureDx would be the third version in the GraftAssure family, following GraftAssureCore which achieved Medicare reimbursement of $2,753 per result.
- Leading medical organizations including the American Medical Association, American Academy of Pediatrics, and Infectious Diseases Society of America have been barred from CDC vaccine advisory workgroups. - The organizations were notified via email that they are considered "special interest groups" with inherent bias, marking a significant departure from decades of collaborative vaccine policy development. - This exclusion follows Health Secretary Robert F. Kennedy Jr.'s dismissal of the entire Advisory Committee on Immunization Practices in June and replacement with vaccine-skeptical members. - Medical experts warn that removing professional medical expertise from the vaccine review process is "irresponsible" and "dangerous to the nation's health."
- A comprehensive study of over 692,000 children found that Tamiflu reduces neuropsychiatric events by 50% compared to untreated influenza, contradicting long-standing safety concerns. - The research analyzed Tennessee Medicaid data from 2016-2020, including 129,000 children treated for influenza, with 67% receiving oseltamivir treatment. - Findings published in JAMA Neurology demonstrate that influenza itself, not Tamiflu treatment, is associated with increased risk of seizures, mood disorders, and self-harm behaviors. - The study provides reassurance to healthcare providers and parents about Tamiflu's safety profile when used early in pediatric influenza treatment.
- A study of 102 older adults found that increasing walking cadence by just 14 steps per minute led to substantial improvements in physical function and frailty outcomes. - Research involving nearly 80,000 predominantly low-income Black Americans demonstrated that 15 minutes of daily brisk walking reduced total mortality by nearly 20%. - Both studies emphasize that walking pace, rather than just duration, is a critical factor in maximizing health benefits from this accessible form of exercise. - The findings support the development of practical interventions, including smartphone apps designed to help seniors monitor and improve their walking cadence.
- UroMems received investigational device exemption approval from the FDA and French ANSM to begin the SOPHIA2 pivotal trial of its UroActive smart implant for treating male stress urinary incontinence. - The UroActive system represents the first automated artificial urinary sphincter with smart technology, utilizing a MyoElectroMechanical System that adapts treatment based on patient activity without complex manipulation. - The multicenter trial follows strong feasibility study results in France showing over one year with no need for revision or explant, with the study serving as the basis for regulatory submissions to commercialize in US and European markets.
- Neumora Therapeutics has initiated a Phase 1 single-ascending dose/multiple-ascending dose study of NMRA-861, a highly potent and selective positive allosteric modulator of the M4 muscarinic receptor for schizophrenia treatment. - The investigational drug demonstrated potential best-in-class pharmacology with no convulsions observed in preclinical studies across multiple species, including rabbits, dogs, and rats. - NMRA-861 targets the M4 muscarinic receptor to elicit antipsychotic effects without the side effects associated with traditional antipsychotics that primarily block D2 dopamine receptors. - The company expects to report Phase 1 data in the first quarter of 2026, including safety, tolerability, and pharmacokinetic data confirming potential for once-daily dosing and central nervous system penetration.
